Firm eyes more partnerships with Chinese pharmaceutical companies to expand its in-licensed drug pipeline as it seeks a larger presence in injectable diabetes therapies
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.